KLOW

KLOW is a proprietary multi-peptide research blend formulated to investigate the combined effects of four mechanistically distinct compounds — BPC-157, TB-500, GHK-Cu, and KPV — on tissue repair, inflammatory signaling, and cellular regeneration. Each component targets a different node in the healing cascade: BPC-157 operates via the FAK-paxillin pathway to promote fibroblast migration and angiogenesis; TB-500 sequesters G-actin through thymosin beta-4 activity to modulate cytoskeletal dynamics and cell motility; GHK-Cu activates over 4,000 genes involved in collagen synthesis, antioxidant defense, and tissue remodeling; and KPV, a tripeptide fragment of alpha-MSH, exerts anti-inflammatory activity via NF-κB pathway inhibition and gut epithelial barrier support.
The synergistic design of KLOW makes it a valuable tool for researchers studying multi-pathway tissue repair models, wound healing cascade interactions, or the combinatorial effects of peptide blends on inflammatory cytokine expression. All four components are independently well-characterized in preclinical literature, and their combination in a single lyophilized formulation allows for streamlined experimental workflows in complex in vitro or in vivo research designs.